Medicare Part D coverage · buspirone hydrochloride · RxCUI 2714184
buspirone hydrochloride 15 MG Oral Capsule [Bucapsol]
Per the CMS 2026 Part D formulary file, buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] is covered by 119 Medicare Part D plans (2.4% of enrollable products), averaging Tier 4.7, with prior authorization required on 0% of covering formularies.
- 2.4%
- Plan coverage
- 119
- Plans covering
- T4.7
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for buspirone hydrochloride 15 MG Oral Capsule [Bucapsol]
Per the CMS 2026 Part D formulary file, buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] (RxNorm concept RXCUI 2714184, generic name buspirone hydrochloride) appears on 3 distinct formulary files spanning 119 Medicare Part D plan offerings - 2.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 5, with a cross-plan average of Tier 4.7.
Real-world access to buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,420,432 Part D beneficiaries filled buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] in 2023, with total plan-and-beneficiary spending of $134,026,806 and an average per-beneficiary annual cost of $94.36. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] today.
Coverage Details
- Formularies covering
- 3
- Plans covering
- 119
- Coverage rate
- 2.4%
- Tier range
- Tier 4 – Tier 5
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,420,432
- Total spending
- $134,026,806
- Avg per beneficiary
- $94.36
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering buspirone hydrochloride 15 MG Oral Capsule [Bucapsol]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] covered by Medicare Part D?
Yes, buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] is covered by 119 Medicare Part D plans (2.4% of all Part D formularies).
What tier is buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] on Medicare Part D plans?
buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] averages Tier 4.7 across Part D plans, ranging from Tier 4 to Tier 5.
Does buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] require prior authorization?
0% of Part D formularies require prior authorization for buspirone hydrochloride 15 MG Oral Capsule [Bucapsol]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on buspirone hydrochloride 15 MG Oral Capsule [Bucapsol]?
In 2023, total Medicare Part D spending on buspirone hydrochloride 15 MG Oral Capsule [Bucapsol] was $134,026,806, covering 1,420,432 beneficiaries. The average spend per beneficiary was $94.36.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- methyltestosterone 10 MG Oral Tablet [Methitest] T4.7
- nitisinone 10 MG Oral Tablet [Nityr] T4.7
- lonafarnib 50 MG Oral Capsule [Zokinvy] T4.7
- amifampridine 10 MG Oral Tablet [Firdapse] T4.7
- 0.1 ML adalimumab-adaz 100 MG/ML Prefilled Syringe T4.7
- 0.2 ML adalimumab-adaz 100 MG/ML Prefilled Syringe T4.7